As drug patents begin to roll off and scrutiny
around drug prices increased over the summer, many pharmaceutical company's struggled.
A thought - provoking discussion on some of the most innovative solutions
around drug pricing and the companies pioneering a new way forward.
Not exact matches
On the surface, Papa seems to have gotten an extraordinarily generous deal to turn
around the beleaguered
drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock
price has fallen nearly 67 % since he took over.
They also said that they would lower the
price of two heart medications, Nitropress and Isuprel,
around 30 % (that's after raising the
prices of the
drugs 525 % and 212 %, respectively).
But they've been hampered by somewhat skeptical physicians who still aren't sure that the
drugs are worth their
price (their topline costs are
around $ 14,000 per treatment course); part of the problem is that it's unclear whether or not those dramatic cholesterol reductions actually translate into broader health outcomes like a reduced risk of stroke or heart attack in heart disease patients.
At the hearing, Dr. David Kimberlin, who specializes in pediatric infectious disease at the University of Alabama at Birmingham, spoke of a situation in September,
around the time Daraprim's
price went up after Turing bought the rights to the
drug, in which he found barriers to getting the
drug because the monthly cost for four tablets suddenly spiked to $ 3,000 from $ 54.
Here's yet another facet of the U.S.
drug pricing conundrum: older treatments which have been
around for years can win label expansions that significantly increase their value, and consequently, their list
prices.
Wall Street «s reaction to the deal was mixed, with some fearing a
price war means the
drug makers have lost ground to the insurers, while others suggested it might be just what «s needed to turn sales of the medicine
around.
Rebates on all of Novo Nordisk's
drugs in North America grew to about 50 percent of list
prices in 2014, from
around 35 percent in 2010, the company said.
Allergan Plc's chief executive on Monday said he was opposed to fundamental changes to the
drug company's business strategy, even as its board considers drastic moves like splitting the company, selling off assets or doing deals to turn
around a steep drop in its share
price.
Acquiring Akorn would add
around $ 1 billion in annual sales to Fresenius» drugmaking division, giving it a significantly larger presence in eyecare and other areas widely perceived as somewhat insulated from generic
drug pricing pressure.
At some
drug stores, the
price for a three - month supply of the lowest starting dose (5 mg) of bisoprolol fumarate is about $ 140, while another beta - blocker, atenolol, costs only
around $ 20 for the lowest starting dose (25 mg)..
If it were a
drug, it would enjoy repeated expensive marketing and a
price tag
around $ 150 per month.
«The
drug smuggler
around the corner would probably be willing to do that for a
price,» Kathryn says.